SCHEMBL1672113

SCHEMBL1672113

O=C(O)Nc1ccc2ccccc2c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 14/20 0.72
NPC1 O15118 13/20 0.72
MAPT P10636 2/20 0.72
MEN1 O00255 7/20 0.65
KMT2A Q03164 7/20 0.65
L3MBTL1 Q9Y468 2/20 0.65
POLB P06746 1/20 0.65
CYP1A2 P05177 2/20 0.64
ALDH1A1 P00352 3/20 0.61
KDM4E B2RXH2 2/20 0.61
CYP2C19 P33261 1/20 0.61
HIF1A Q16665 1/20 0.61
SMN1; SMN2 Q16637 3/20 0.57
TDP1 Q9NUW8 1/20 0.57
GAA P10253 1/20 0.57
HSD17B10 Q99714 2/20 0.55
LMNA P02545 2/20 0.55
PKM P14618 1/20 0.55
USP2 O75604 1/20 0.55
TP53 P04637 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7450826 0.89 RAB9A (0.60) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL9547503 0.85 RAB9A (0.89) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL30697002 0.84 MAPT (1.00) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL11049543 0.84 MAPT (1.00) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL15727595 0.84 RAB9A (0.68) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL3608965 0.83 RAB9A (0.67) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL2229842 0.82 NPC1 (0.76) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL516844 0.82 RAB9A (0.65) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL8203018 0.82 NPC1 (0.50) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL516845 0.82 RAB9A (0.65) RAB9ANPC1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11326018-B2 Process for the synthesis of polyoxazolidinone compounds COVESTRO DEUTSCHLAND AG (DE) 2022-05-10 US claimed
US-11319398-B2 Method for the production of polyoxazolidinone polymer compounds COVESTRO DEUTSCHLAND AG (DE) 2022-05-03 US claimed
EP-3577149-B1 METHOD FOR THE PRODUCTION OF POLYOXAZOLIDINONE POLYMER COMPOUNDS COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) 2022-02-09 EP claimed
US-20210284785-A1 PROCESS FOR THE SYNTHESIS OF POLYOXAZOLIDINONE COMPOUNDS COVESTRO DEUTSCHLAND AG (DE) 2021-09-16 US claimed
EP-3500611-B1 PROCESS FOR THE SYNTHESIS OF POLYOXAZOLIDINONE COMPOUNDS COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) 2021-08-11 EP claimed
CN-109642010-B Synthesis method of polyoxazolidone compound 科思创德国股份有限公司 2021-06-04 CN claimed
US-20210130527-A1 METHOD FOR THE PRODUCTION OF POLYOXAZOLIDINONE POLYMER COMPOUNDS COVESTRO DEUTSCHLAND AG (DE) 2021-05-06 US claimed
US-10385167-B2 Process for the synthesis of polyoxazolidinone compounds with high stability COVESTRO DEUTSCHLAND AG (DE) 2019-08-20 US claimed
EP-3500611-A1 PROCESS FOR THE SYNTHESIS OF POLYOXAZOLIDINONE COMPOUNDS Covestro Deutschland AG (DE) 2019-06-26 EP claimed
CN-109642010-A The synthetic method of poly- Oxazolidinone compound 科思创德国股份有限公司 2019-04-16 CN claimed
US-20180022871-A1 PROCESS FOR THE SYNTHESIS OF POLYOXAZOLIDINONE COMPOUNDS WITH HIGH STABILITY COVESTRO DEUTSCHLAND AG (DE) 2018-01-25 US claimed
EP-1353926-B1 MIKANOLIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USES SOD CONSEILS RECH APPLIC (FR) 2006-03-08 EP claimed
JP-2004533456-A 2004-11-04 JP claimed
US-20040142999-A1 Novel compounds and compositions as cathepsin inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2004-07-22 US claimed
EP-1438039-A2 PRODUCT COMPRISING MIKANOLIDE, DIHYDROMIKANOLIDE OR AN ANALOGUE THEREOF COMBINED WITH ANOTHER ANTI-CANCER AGENT FOR THERAPEUTIC USE IN CANCER TREATMENT SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-07-21 EP claimed
EP-1397340-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2004-03-17 EP claimed
EP-1353926-A1 MIKANOLIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USES Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) 2003-10-22 EP claimed
WO-2002098850-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-12-12 WO claimed
WO-2002096348-A2 PRODUCT COMPRISING MIKANOLIDE, DIHYDROMIKANOLIDE OR AN ANALOGUE THEREOF COMBINED WITH ANOTHER ANTI-CANCER AGENT FOR THERAPEUTIC USE IN CANCER TREATMENT SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2002-12-05 WO claimed
WO-2002055523-A1 MIKANOLIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2002-07-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142999-A1 Novel compounds and compositions as cathepsin inhibitors CTSS, CTSB, CTSE RAB9A 512/4885NPC1 37/4885MAPT 2065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.